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Collective evidence suggests that cyclooxygenase 2 (COX2) plays a role in prostate cancer risk. Cyclooxygenase 2 is the major
enzyme that converts arachidonic acid to prostaglandins, which are potent mediators of inflammation. Nonsteroidal anti-inflammatory
drugs (NSAIDs) inhibit the enzymatic activity of COX2 and long-term use of NSAIDs appears to modestly lower the risk of prostate
cancer. We investigated whether common genetic variation in COX2 influences the risk of advanced prostate cancer. Nine single-
nucleotide polymorphisms (SNPs) in COX2 were genotyped among 1012 men in our case–control study of advanced prostate
cancer. Gene–environment interactions between COX2 polymorphisms and NSAID use were also evaluated. Information on NSAID
use was obtained by questionnaire. Three SNPs demonstrated nominally statistically significant associations with prostate cancer risk,
with the most compelling polymorphism (rs2745557) associated with a lower risk of disease (odds ratio (OR) GC vs GG¼0.64; 95%
confidence interval (CI): 0.49–0.84; P¼0.002). We estimated through permutation analysis that a similarly strong result would occur
by chance 2.7% of the time. Nonsteroidal anti-inflammatory drug use was associated with a lower risk of disease in comparison to
no use (OR¼0.67; 95% CI: 0.52–0.87). No significant statistical interaction between NSAID use and rs2745557 was observed
(P¼0.12). Our findings suggest that variation in COX2 is associated with prostate cancer risk.
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Cyclooxygenase 2 (COX2) is an inducible enzyme that converts
arachidonic acid to prostaglandins, which are potent mediators of
inflammation. Through the production of prostaglandins, COX2
is hypothesised to influence carcinogenesis by promoting cell
proliferation, inhibiting apoptosis, stimulating angiogenesis, and
mediating immune suppression (Kirschenbaum et al, 2001; Fujita
et al, 2002; Nithipatikom et al, 2002; Wang et al, 2005). Multiple
studies have shown increased expression of COX2 in prostate
tumours (Gupta et al, 2000; Kirschenbaum et al, 2000; Tanji et al,
2000; Yoshimura et al, 2000; Uotila et al, 2001), although one study
reported overexpression not in tumour tissue but rather in
proliferative inflammatory atrophy, a putative precursor lesion
of prostate cancer (Zha et al, 2001). More recently, increased COX2
expression has been correlated with higher tumour grade (Wang
et al, 2005) and prostate cancer progression (Cohen et al, 2006).
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the
enzymatic activity of COX2, and inhibitors of COX2 suppress the
growth of prostate cancer cells in vitro as well as prostate
tumorigenesis in vivo (Liu et al, 2000; Gupta et al, 2004; Patel et al,
2005; Narayanan et al, 2006). Furthermore, long-term use of
NSAIDs has been associated with a reduction in prostate cancer
risk (OR¼0.81; 95% CI: 0.70–0.94) among the American Cancer
Society’s Cancer Prevention Study II Nutrition Cohort, the largest
prospective study to date of NSAIDs and prostate cancer having
5539 cases of prostate cancer (Jacobs et al, 2007).
Recently, two studies demonstrated that variants in COX2
were associated with the risk of prostate cancer (Panguluri et al,
2004; Shahedi et al, 2006). In one study of African Americans,
Nigerians, and European Americans, four promoter variants in
COX2 were evaluated and divergent patterns of association were
observed across the three groups (Panguluri et al, 2004).
Two variants,  1265 G/A (rs20415) and  899 G/C (rs20417),
were associated with an increased risk of prostate cancer among
African Americans, while the  297 C/G (rs5270) variant was
associated with a reduced risk overall and among African
Americans and European Americans (Panguluri et al, 2004). In a
second study of a Swedish population, five COX2 variants were
examined and two variants, þ3100 C/T (rs689470) and þ8365 C/
T (rs2043), were associated with a reduced risk of disease (Shahedi
et al, 2006).
In light of the strong support for the involvement of COX2 in
prostate carcinogenesis coupled with the initial evidence that
inherited differences in COX2 may impact risk of disease, we
evaluated the association between common genetic variation in
COX2 and prostate cancer risk in a case–control study of advanced
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sprostate cancers. To date, this is the most comprehensive study of
the genetic diversity of COX2. In addition, we investigated the
possible interactive effects of COX2 variation and NSAID use on
prostate cancer risk.
METHODS
Study subjects
We recruited 506 advanced incident prostate cancer cases and 506
controls from the major medical institutions in Cleveland, Ohio
(The Cleveland Clinic, University Hospitals of Cleveland, and
their affiliates). Advanced prostate cancer cases were confirmed
histologically and defined as having either a Gleason score X7, or
TNM stage XT2c, or PSA at diagnosis 410ngml
 1. Cases were
contacted shortly following diagnosis (median time between
diagnosis and recruitment¼4.7 months). Restricting the cases to
men diagnosed with advanced disease allows us to focus on the
most clinically relevant prostate cancers. To help ensure that the
controls were representative of the source population of the cases,
controls were men who underwent standard annual medical exams
at the collaborating medical institutions. Controls had no
diagnosis of prostate cancer or any other non-skin cancers. All
controls received a PSA test to detect occult prostate cancer.
Controls were frequency matched to cases by age (within 5 years),
ethnicity, and medical institution. Detailed information and
descriptive characteristics for this case–control study has been
reported previously (Liu et al, 2006).
Institutional Review Board approval was obtained from the
participating medical institutions, and informed consent was
obtained from all study participants.
Tag SNP selection
We evaluated the genetic structure of COX2 by using publicly
available genotype data for European populations from the
International HapMap project (www.hapmap.org) (Altshuler
et al, 2005) and the Perlegen and Seattle SNP projects (National
Heart, Lung, and Blood Institute Genome Variation Server;
http://gvs.gs.washington.edu/GVS/). We assessed the common genetic
variation of COX2 (SNPs with minor allele frequencies (MAF)
45%) that spanned B2 kilobases (kb) upstream of the transcrip-
tion start site and B1kb downstream of the 30 untranslated (UTR)
region. For genetic characterization, seven SNPs (average
density¼1 SNP every 1.4kb) and 14 SNPs (average density¼1
SNP every 510bp) were used from the HapMap and Perlegen/
Seattle data, respectively. To thoroughly capture the common
genetic variation across the locus, we utilised a pairwise tagging
approach that reconstructed all SNPs across the locus (Carlson
et al, 2004; de Bakker et al, 2005), using a criterion of a minimum
pairwise r
2X0.8 between the tag SNP and unmeasured SNP. The
Tagger website (http://ww.broad.mit.edu/tagger) and Genome
Variation Server (http://gvs.gs.washington.edu/GVS/) were used
for tag SNP selection (Carlson et al, 2004; de Bakker et al, 2005).
We did not attempt to capture the genetic variation of African
populations because our sample size did not have sufficient power
to conduct African American-specific analyses.
First using the HapMap data, we selected six tag SNPs (rs689466,
rs2745557, rs2206593, rs4648307, rs4648261, and rs5272) to
capture the common genetic variation across COX2 (mean
r
2¼1.0). Because genotyping assays for two SNPs (rs4648307,
rs4648261) could not be designed and one SNP (rs5272) was
monomorphic in our study population, we subsequently used the
Perlegen and Seattle SNP data to maintain a comprehensive
evaluation of the COX2 locus. Using this data, we selected five tag
SNPs (rs5277, rs2066826, rs5275, rs4648310, and rs689467)
exclusive from the tag SNPs identified from HapMap. A genotype
assay could not be designed for rs689467.
Two common SNPs, þ8365 C/T (rs689470) and  899 G/C
(rs20417), that were previously associated with prostate cancer
(Panguluri et al, 2004; Shahedi et al, 2006) were also included as
tag SNPs. In total, nine tag SNPs were selected for our case–
control study: rs689466, rs20417, rs2745557, rs5277, rs2066826,
rs5275, rs2206593, rs689470 and rs4648310.
Genotyping
Genotyping was performed using the 50 nuclease Taqman allelic
discrimination assay using the manufacturer’s predesigned primer/
probe sets (rs5277, rs5275, rs2206593, rs689470) or custom-
designed and manufactured primer/probe sets (rs689466,
rs20417, rs2745557, rs2066826, rs4648310) (Applied Biosystems,
Foster City, CA, USA). All assays were undertaken by individuals
blinded to case–control status. For quality control, 2% replicate
samples were included. The concordance rate for replicate samples
was 100%. The average genotyping success rate was 99.9%. Further
details of genotyping methods are described elsewhere (Liu et al,
2006). All SNPs were in Hardy–Weinberg equilibrium (at P40.01
level).
Nonsteroidal anti-inflammatory drugs
During an in-person computer-aided personal interview, men were
asked about the amount and duration of previous aspirin and
ibuprofen drug use (other types of NSAIDs were not assessed). We
defined NSAID use as either aspirin or ibuprofen consumption at
least twice a week for more than 1 month and no use as less than
twice a week use of either of the medications for less than 1 month.
For the dose/duration of use, we determined ‘pill-years’, which is
the product of number of pills taken per day and years of drug use,
for aspirin and ibuprofen. The summation of pill-years of aspirin
use and ibuprofen use is the dose/duration of any NSAID
consumption.
To investigate the hypothesis that genetic susceptibility to
prostate cancer risk is associated with single causal variants, we
evaluated the relationship between COX2 genotypes and prostate
cancer risk. Odds ratios (ORs) and 95% confidence intervals (CI)
were estimated by unconditional logistic regression to examine the
association between COX2 SNPs and prostate cancer risk.
To potentially capture other unmeasured variants that may not
be adequately captured by single markers, we evaluated the
relationship between common COX2 haplotypes and prostate risk.
Haplotype frequencies among prostate cancer cases and controls
were estimated by using genotype data of the tag SNPs as described
by Stram et al (2003). Haplotype dosage (i.e. an estimate of the
number of copies of haplotype h) for each individual and each
haplotype, h, was computed using that individual’s genotype data
and haplotype frequency estimates were obtained from the E-M
algorithm (Zaykin et al, 2002). Odds ratios and 95% CIs were then
estimated by unconditional logistic regression for the association
between COX2 haplotypes and prostate cancer risk.
To examine the interaction between COX2 genotypes and NSAID
use, we dichotomized the latter into use and no use and assessed
the effect of NSAID use stratified by COX2 genotypes. To test for
statistical interaction, the model contained separate terms for the
main effect of COX2 genotype, the main effect of NSAID use, and
an interaction term for the cross product of COX2 genotype and
NSAID use. We also tested the interaction between COX2
genotypes and dose/duration of NSAIDs (categorised into tertiles
based on the distribution among controls).
All OR estimates were adjusted for age and medical institution
and also for racial/ethnic group in any analysis that combined
groups. All reported P-values are two-sided. Permutation testing
was conducted to guide interpretation of nominally statistically
significant SNP associations. Case–control status within strata
of age (p62, 63–70, and 470 years), racial/ethnic group, and
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nine COX2 SNPs.
RESULTS
First, we tested the association between COX2 SNPs and prostate
cancer risk in our study of 506 advanced cases and 506 controls.
Three SNPs (rs2745557, rs2206593, and rs689470) were nominally
statistically significantly associated with prostate cancer risk
(Table 1). The strongest association was seen with rs2745557
(P¼0.002); specifically, men carrying the GA genotype in
comparison to men carrying the GG genotype had a significantly
lower risk of disease (OR¼0.64; 95% CI: 0.49–0.84). An overall
consistent pattern of the GA genotype was seen across racial/ethnic
groups (Table 1). Similarly, a lower risk of prostate cancer was
observed for the CT genotype of rs2206593 (OR¼0.58; 95% CI:
0.38–0.89); this polymorphism was moderated linked with
rs2745557 (D0 ¼1.00; r
2¼0.35). In contrast, a higher risk of
disease was observed with the AA genotype of rs689470 in
comparison to the GG genotype (OR¼2.57; 95% CI: 1.17–5.64),
with this SNP being more common among African Americans than
Caucasians (MAF: 38 vs 2%, respectively). Overall, rs2745557
demonstrated the most compelling association with prostate
cancer risk and its permutation P-value was 0.027, indicating that
when permuting the data similar levels of significance were
observed 2.7% of the time.
Next, we tested the association between COX2 haplotypes and
prostate cancer risk (Table 2). We identified one strong region of
linkage disequilibrium (rs689466–rs5275) among Caucasians with
six common haplotypes (45%). A significant global haplotype
effect for prostate cancer risk was observed (P¼0.03). We
observed a nominally significant association between the AGGGGA
haplotype and prostate cancer risk (P¼0.009). This haplotype
could be defined by the G allele of rs5277, which was associated
with risk among Caucasians (CG/GG vs CC: OR¼1.36; 95% CI:
1.01–1.83).
We examined the potential interactive effects between the
rs2745557 SNP and NSAIDs (Table 3). We previously reported an
inverse association between NSAID use and prostate cancer risk in
this study (OR¼0.67; 95% CI: 0.52–0.87) (Liu et al, 2006). No
significant statistical interaction was observed between rs2745557
and NSAID use (P¼0.12). Among men carrying the GG genotype
of rs2745557, a significant reduced risk of prostate cancer was
observed with NSAID use (OR¼0.58; 95% CI: 0.42–0.79). In
contrast, among men carrying the GA/AA genotype of rs2745557,
there was no significant effect with NSAID use. Similar patterns
of associations were observed across racial/ethnic groups. No
statistical interaction was observed between rs2745557 and dose/
duration of NSAIDs (P¼0.97).
DISCUSSION
In this comprehensive evaluation of COX2, we identified a
polymorphism (rs2745557) that was associated with a 36%
reduction in risk of prostate cancer (P¼0.002). In addition, the
major G allele of this polymorphism in combination with NSAID
use demonstrated an B40% lower risk of disease in comparison
with the G allele and no NSAID use, while the minor A allele was
associated with an B50% lower risk and was not influenced by
NSAID use. However, a statistically significant interactive effect
between rs2745557 and NSAID was not achieved. Our results
suggest that inherited variation in COX2 influences prostate cancer
susceptibility.
In comparison with the previous study that detected an
association between the  899 G/C (rs20417) variant and prostate
cancer among African Americans (Panguluri et al, 2004), we did
not detect any association with this SNP. Furthermore, while the
previous Swedish study detected an inverse association between
the þ3100 C/T (rs689470) variant and prostate cancer (Shahedi
et al, 2006), we observed no such association among Caucasians.
However, we did observe a positive association with this variant
among African Americans (Table 1). Reasons for these conflicting
results are unclear and may be due to our limited power to detect
rare effects (Caucasians: MAF¼0.02 vs African Americans:
MAF¼0.38).
Our finding of an association between rs2745557 and prostate
cancer risk was robust when subjected to permutation testing.
Permutation testing empirically evaluates the robustness of
nominally significant P-values and guides the interpretation of
results when multiple hypotheses are tested (Hirschhorn and Daly,
2005). We determined that the genotype effect we observed would
have occurred by chance less than B3% of the time. This
demonstrates that COX2 is a solid candidate gene for prostate
cancer susceptibility and warrants further investigation.
Spurious association due to population stratification in our
study is unlikely. For example, population stratification could
occur if there is overrepresentation of African-American alleles
among cases in comparison to controls. By matching cases and
controls on racial/ethnic group as well as medical institution, the
likelihood that population stratification may have biased our
results is low. Moreover, we observed consistent effects among
both African Americans and Caucasians, indicating that large-scale
bias due to underlying population structure is unlikely to have
occurred.
Our study has several limitations. Because of limited power to
conduct African American-specific analyses, we did not characterise
the common genetic variation of COX2 among this population.
Thus, we could not thoroughly assess the relationship between
COX2 variants and prostate cancer risk among African Americans.
In addition, our study cannot exclude the possibility of an
association between rare variants in COX2 (MAF o5%) and
prostate cancer risk.
The functional impact of rs2745557, an intronic variant, on
COX2 activity is not yet known. It is possible that either this
polymorphism itself or another linked marker may have biological
effects on COX2 activity. We hypothesise that genetic variation in
COX2 may alter the production of inflammatory prostaglandins,
which could ultimately influence prostate cancer susceptibility.
Furthermore, environmental factors such as use of NSAIDs may
modify the biological effects of COX2 variation on disease risk. In
particular, the combined effects of rs2745557 and NSAID use are of
interest. Among men with the major allele of this polymorphism,
those who were NSAID users had a slightly lower risk of prostate
cancer than those who were non-NSAID users. While men with the
minor allele of this polymorphism appeared to have no additional
benefit of NSAID use, it is plausible that NSAID use may actively
inhibit COX2 enzymatic activity only among those with the more
prevalent major allele, while those with the variant allele may reach
a threshold of COX2 inhibition such that NSAID use provides no
added protection. To fully explore these potential interactive
effects, larger well-powered studies are needed.
We previously reported that a functional variant (LTA Cþ80A)
in lymphotoxin alpha, a proinflammatory cytokine, modified the
protective effect of NSAIDs on prostate cancer (Liu et al, 2006).
Specifically, a stronger inverse association between NSAIDs and
prostate cancer was observed among men carrying the CC
genotype (OR¼0.43; 95% CI: 0.28–0.67). To further investigate
the influence of the LTA Cþ80A variant on COX2 and NSAID use,
we examined the combined effects of rs2745557 and NSAIDs
stratified by the CC and AC/AA genotypes for the LTA Cþ80A
variant. Among men with the CC genotype for LTA Cþ80A, an
88% reduction in risk was observed among those with the AG/AA
genotype for rs2745557 and who were also NSAIDs users
(Po0.0001). Such findings highlight the complex nature of
prostate cancer susceptibility, which is likely due to multiple
COX2, NSAIDs, and advanced prostate cancer
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sTable 1 Associations between COX2 variants and prostate cancer risk
All groups
a African Americans
b Caucasians
b
SNP
Cases, n
(%)
Controls,
n (%) OR (95% CI)
Cases, n
(%)
Controls, n
(%) OR (95% CI)
Cases, n
(%)
Controls, n
(%) OR (95% CI)
rs689466 AA 337 (66.6) 357 (70.6) 1.00 67 (75.3) 77 (86.5) 1.00 270 (49.1) 280 (67.2) 1.00
AG 154 (30.4) 134 (26.5) 1.22 (0.93–1.61) 20 (22.5) 12 (13.5) 1.94 (0.88–4.28) 134 (32.1) 122 (29.3) 1.14 (0.85–1.53)
GG 15 (3.0) 15 (3.0) 1.06 (0.51–2.21) 2 (2.3) 0 (0) — 13 (3.1) 15 (3.6) 0.90 (0.42–1.92)
rs20417
c GG 332 (65.7) 331 (65.5) 1.00 38 (42.7) 38 (43.2) 1.00 294 (70.7) 293 (70.3) 1.00
GC 157 (31.1) 151 (29.9) 1.03 (0.78–1.36) 42 (47.2) 38 (43.2) 1.10 (0.59–2.07) 115 (27.6) 113 (27.1) 1.01 (0.75–1.38)
CC 16 (3.2) 23 (4.6) 0.68 (0.35–1.33) 9 (10.1) 12 (13.6) 0.75 (0.28–1.99) 7 (1.7) 11 (2.6) 0.63 (0.24–1.66)
rs2745557 GG 364 (71.9) 318 (62.9) 1.00 69 (77.5) 56 (62.9) 1.00 295 (70.7) 262 (62.8) 1.00
GA 126 (24.9) 172 (34.0) 0.64 (0.49–0.84)
e 19 (21.4) 30 (33.7) 0.51 (0.26–1.01) 107 (25.7) 142 (34.1) 0.67 (0.50–0.90)
f
AA 16 (3.2) 16 (3.2) 0.87 (0.43–1.78) 1 (1.1) 3 (3.4) 0.27 (0.03–2.68) 15 (3.6) 13 (3.1) 1.02 (0.48–2.20)
rs5277 CC 359 (71.1) 384 (75.9) 1.00 86 (96.6) 83 (93.3) 1.00 273 (65.6) 301 (72.2) 1.00
CG 134 (26.5) 116 (22.9) 1.25 (0.93–1.68) 3 (3.4) 6 (6.7) 0.48 (0.12–1.99) 131 (31.5) 110 (26.4) 1.32 (0.97–1.78)
GG 12 (2.4) 6 (1.2) 2.18 (0.81–5.90) 0 (0) 0 (0) — 12 (2.9) 6 (1.4) 2.21 (0.82–5.99)
rs2066826 AA 353 (69.8) 341 (67.5) 1.00 39 (43.8) 32 (36.4) 1.00 314 (75.3) 309 (74.1) 1.00
AG 140 (27.7) 142 (28.1) 0.94 (0.70–1.25) 42 (47.2) 44 (50.0) 0.78 (0.42–1.47) 98 (23.5) 98 (23.5) 0.98 (0.71–1.36)
GG 13 (2.6) 22 (4.4) 0.55 (0.27–1.13) 8 (9.0) 12 (13.6) 0.55 (0.20–1.50) 5 (1.2) 10 (2.4) 0.49 (0.17–1.46)
rs5275 AA 195 (38.6) 207 (40.9) 1.00 12 (13.5) 11 (12.4) 1.00 183 (44.0) 196 (47.0) 1.00
AG 238 (47.1) 226 (44.7) 1.06 (0.70–1.58) 39 (43.8) 49 (55.1) 0.73 (0.29–1.85) 199 (47.8) 177 (42.5) 1.21 (0.91–1.60)
GG 72 (14.3) 73 (14.4) 1.12 (0.86–1.47) 38 (42.7) 29 (32.6) 1.20 (0.46–3.14) 34 (8.2) 44 (10.6) 0.83 (0.51–1.35)
rs2206593
d CC 466 (92.1) 438 (86.7) 1.00 87 (97.8) 85 (96.6) 1.00 379 (90.9) 353 (84.7) 1.00
CT 40 (7.9) 64 (12.7) 0.58 (0.38–0.89)
g 2 (2.3) 3 (3.4) 0.65 (0.11–4.01) 38 (9.1) 61 (14.6) 0.58 (0.38–0.89)
h
TT 0 (0) 3 (0.6) — 0 (0) 0 (0) — 0 (0) 3 (0.7) —
rs689470 GG 422 (83.6) 434 (85.9) 1.00 25 (28.1) 33 (37.5) 1.00 397 (95.4) 401 (96.2) 1.00
GA 57 (11.3) 58 (11.5) 1.19 (0.73–1.93) 39 (43.8) 43 (48.9) 1.20 (0.61–2.37) 18 (4.3) 15 (3.6) 1.21 (0.60–2.43)
AA 26 (5.2) 13 (2.6) 2.57 (1.17–5.64)
i 25 (28.0) 12 (13.6) 2.79 (1.17–6.64)
j 1 (0.2) 1 (0.2) 1.00 (0.06–16.21)
rs4648310 AA 473 (93.5) 485 (95.9) 1.00 88 (98.9) 87 (97.8) 1.00 385 (92.3) 398 (95.4) 1.00
AG 30 (5.9) 20 (4.0) 1.54 (0.86–2.76) 1 (1.1) 2 (2.3) 0.49 (0.04–5.60) 29 (7.0) 18 (4.3) 1.67 (0.91–3.05)
GG 3 (0.6) 1 (0.2) 3.10 (0.32–29.97) 0 (0) 0 (0) — 3 (0.7) 1 (0.2) 3.12 (0.32–30.12)
aAdjusted for age, ethnicity, and institution.
bAdjusted for age and institution.
crs20417¼ 899G/C.
drs689470¼+3100 C/T (reverse strand alleles).
eP¼0.002;
fP¼0.011;
gP¼0.019;
hP¼0.021;
iP¼0.009;
jP¼0.013.
Table 2 Associations between COX2 haplotypes and prostate cancer risk among Caucasians
a
rs689466 rs20417 rs2745557 rs5277 rs2066826 rs5275
Haplotype % in
cases/controls OR (95% CI)
A G A C G A 16/20 1.00
G G G C G A 19/18 1.29 (0.94–1.77)
A G G C G G 17/16 1.30 (0.94–1.81)
A G G G G A 19/15 1.56 (1.12–2.19)
b
A G G C G A 13/15 1.09 (0.78–1.53)
A C G C A G 13/14 1.12 (0.79–1.59)
aAdjusted for age and institution.
bP¼0.009.
Table 3 Odd ratios and 95% CIs for prostate cancer risk associated with COX2 rs2745557 and NSAID use
rs2745557 GG rs2745557 GA/AA
NSAID Cases, n (%) Controls, n (%) OR (95% CI) Cases, n (%) Controls, n (%) OR (95% CI)
All groups
a No 264 (64.7) 144 (43.6) 1.00 64 (45.1) 80 (42.6) 1.00
Yes 413 (61.0) 186 (56.4) 0.58 (0.42–0.79)
b 78 (54.9) 108 (57.5) 0.86 (0.55–1.35)
African Americans
c No 44 (63.6) 24 (42.9) 1.00 14 (70.0) 22 (66.7) 1.00
Yes 25 (36.2) 32 (57.1) 0.44 (0.21–0.91)
d 6 (30.0) 11 (33.3) 0.73 (0.21–2.56)
Caucasians
c No 119 (40.5) 77 (29.8) 1.00 50 (41.0) 58 (37.4) 1.00
Yes 175 (59.5) 181 (70.2) 0.62 (0.43–0.89)
e 72 (59.0) 97 (62.6) 0.86 (0.53–1.40)
aAdjusted for age, ethnicity, and institution.
bP¼0.0007.
cAdjusted for age and institution.
dP¼0.0258;
eP¼0.0089.
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components.
In this study, we demonstrate that common genetic variation in
COX2 influences the risk of prostate cancer. To date, this is the
most comprehensive survey of common genetic variation at the
COX2 locus. Our finding supports previous reports showing an
association between COX2 variants and prostate cancer risk.
Replication is critical in establishing an association between a
variant and disease and additional studies either confirming or
refuting these findings are needed. Furthermore, our study
provides supporting evidence for the overall role of inflammation
in prostate cancer susceptibility. By examining how inherited
variation in inflammatory genes impacts risk of disease, we will
further advance our understanding of prostate carcinogenesis and
disease susceptibility.
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